natgillin/translations-raw huggingface dataset:
The detection of MDPV has also been reported in biological samples related to fatal and non-fatal road traffic accidents, or driving under the influence of drugs, in four Member States since 2009.
U četirima državama članicama od 2009. prijavljeno je otkrivanje MDPV-a i u biološkim uzorcima koji su povezani s prometnim nesrećama sa smrtnim posljedicama i prometnim nesrećama bez smrtnih posljedica ili s vožnjom pod utjecajem droge.
MDPV has been present on the Union drug market since November 2008, and 27 Member States, Norway and Turkey have reported multi-kilogram seizures of the substance.
MDPV je na Unijinom tržištu droge prisutan od studenoga 2008. te su 27 država članica, Norveška i Turska prijavile zapljene više kilograma te tvari.
MDPV is being sold as a substance in its own right, but it has also been detected in combination with other substances.
MDPV se prodaje kao samostalna tvar, ali je otkriven i u kombinaciji s drugim tvarima.
It is widely available from internet suppliers and retailers, ‘head shops’ and street-level dealers.
Široko je dostupan kod internetskih dobavljača i prodavatelja, u specijaliziranim trgovinama (head shops) i kod uličnih dilera.
There are some indications that suggest a degree of organisation in the tableting and distribution of this substance in the Union.
Postoje neke naznake koje ukazuju na određeni stupanj organizacije u proizvodnji tableta i distribuciji te tvari u Uniji.
The Risk Assessment Report reveals that further research would be needed to determine the health and social risks posed by MDPV.
Iz izvješća o procjeni rizika proizlazi da će biti potrebno daljnje istraživanje kako bi se utvrdili zdravstveni i socijalni rizici koje MDPV predstavlja.
However, the available evidence and information provides sufficient ground for subjecting MDPV to control measures across the Union.
Međutim, trenutačno dostupni dokazi i informacije predstavljaju dovoljnu osnovu za podvrgavanje MDPV-a kontrolnim mjerama širom Unije.
As a result of the health risks that it poses, as documented by its detection in several reported fatalities, of the fact that users may unknowingly consume it, and of the lack of medical value or use of the substance, MDPV should be subjected to control measures across the Union.
Zbog zdravstvenih rizika koje on predstavlja, kao što je dokumentirano njegovim otkrivanjem u više prijavljenih smrtnih slučajeva, činjenice da ga korisnici mogu nesvjesno konzumirati i nepostojanja medicinske vrijednosti ili uporabe te tvari, MDPV bi trebalo podvrgnuti kontrolnim mjerama diljem Unije.
Given that 21 Member States control MDPV under national legislation complying with the obligations of the 1971 United Nations Convention on Psychotropic Substances, and that four Member States use other legislative measures to control it, subjecting this substance to control measures across the Union would help avoid the emergence of obstacles in cross-border law enforcement and judicial cooperation, and would protect against the risks that its availability and use can pose.
S obzirom na to da 21 država članica kontrolira tvar MDPV u okviru nacionalnog zakonodavstva kojim se poštuju obveze na temelju Konvencije Ujedinjenih naroda o psihotropnim tvarima iz 1971. i da četiri države članice upotrebljavaju druge zakonodavne mjere za njezinu kontrolu, podvrgavanje te tvari kontrolnim mjerama širom Unije pomoglo bi izbjegavanju pojave prepreka u prekograničnom izvršavanju zakona i pravosudnoj suradnji te bi pružilo zaštitu od rizika koje dostupnost i uporaba te tvari mogu predstavljati.
Methoxetamine is an arylcyclohexylamine substance which is chemically similar to ketamine and the internationally-controlled substance phencyclidine (PCP).
Metoksetamin je arilcikloheksilamin koji je kemijski sličan ketaminu i tvari koja je pod međunarodnom kontrolom, fenciklidinu (PCP).
Like ketamine and PCP, it has dissociative properties.
Metoksetamin, poput ketamina i PCP-a, ima disocijacijska svojstva.
There are no studies assessing the chronic and acute toxicity associated with methoxetamine, as well as its psychological and behavioural effects and dependence potential.
Ne postoje studije u kojima se procjenjuju kronična i akutna toksičnost povezane s metoksetaminom te njegove psihološke i bihevioralne posljedice i ovisnički potencijal.
Self-reported experiences from user websites suggest adverse effects similar to ketamine intoxication.
Iskustva samih korisnika s korisničkih internetskih stranica ukazuju na štetne učinke slične trovanju ketaminom.
These include nausea and severe vomiting, difficulty in breathing, seizures, disorientation, anxiety, catatonia, aggression, hallucination, paranoia and psychosis.
Ti učinci obuhvaćaju mučninu i jako povraćanje, poteškoće s disanjem, napadaje, dezorijentiranost, anksioznost, katatoniju, agresiju, halucinacije, paranoju i psihozu.
In addition, acute methoxetamine intoxications may include stimulant effects (agitation, tachycardia and hypertension) and cerebral features, which are not expectable with acute ketamine intoxication.
Osim toga, akutno trovanje metoksetaminom može uključivati stimulativne učinke (agitacija, tahikardija i hipertenzija) i cerebralne promjene koje nisu očekivane u slučaju akutnog trovanja ketaminom.
Twenty deaths associated with methoxetamine have been reported by six Member States that detected the substance in post-mortem samples.
Šest država članica prijavile su 20 smrtnih slučajeva povezanih s metoksetaminom, pri čemu je ta tvar otkrivena u obdukcijskim uzorcima.
Used alone or in combination with other substances, methoxetamine was detected in 20 non-fatal intoxications reported by five Member States.
Pet država članica prijavile su da je metoksetamin, sam ili u kombinaciji s drugim tvarima, otkriven u 20 trovanja bez smrtnih posljedica.
Twenty-three Member States, Turkey and Norway have reported that they reported detection of methoxetamine, since November 2010.
Od studenoga 2010. dvadeset tri države članice, Turska i Norveška prijavile su da su prijavile otkrivanje metoksetamina.
Information suggests that it is sold and used as a substance in its own right, and that it is also sold as a ‘legal’ replacement for ketamine by internet retailers, ‘head shops’ and street-level drug dealers.
Informacije ukazuju na to da se metoksetamin prodaje i upotrebljava kao samostalnu tvar te na to da ga internetski prodavatelji, specijalizirane trgovine (head shops) i ulični dileri droge također prodaju kao „legalnu” zamjenu za ketamin.
Multi-kilogram quantities in powder form have been seized within the Union, but there is no information on the possible involvement of organised crime.
U Uniji je zaplijenjeno više kilograma u obliku praha, ali nema informacija o mogućem sudjelovanju organiziranog kriminala.
The manufacture of methoxetamine does not require sophisticated equipment.
Za proizvodnju metoksetamina nije potrebna sofisticirana oprema.
Prevalence data are limited to non-representative studies in two Member States.
Podaci o raširenosti uporabe ograničeni su na nereprezentativne studije u dvjema državama članicama.
Those studies suggest that the prevalence of the use of methoxetamine is lower than that of ketamine.
Te studije ukazuju na to da je raširenost uporabe metoksetamina niža od raširenosti uporabe ketamina.
The available information suggests that it may be consumed in a wide range of settings, including at home, in bars, in nightclubs and at music festivals.
Dostupne informacije ukazuju na to da se može konzumirati na različitim mjestima, na primjer u domu, u barovima, u noćnim klubovima te na glazbenim festivalima
The Risk Assessment Report reveals that further research would be needed to determine the health and social risks posed by methoxetamine.
Iz izvješća o procjeni rizika proizlazi da će biti potrebno daljnje istraživanje kako bi se utvrdili zdravstveni i socijalni rizici koje metoksetamin predstavlja.
However, the available evidence and information provides sufficient grounds for subjecting methoxetamine to control measures across the Union.
Međutim, trenutačno dostupni dokazi i informacije predstavljaju dovoljnu osnovu za podvrgavanje metoksetamina kontrolnim mjerama širom Unije.
As a result of the health risks that it poses, as documented by its detection in several reported fatalities, of the fact that users may unknowingly consume it, and of the lack of medical value or use, methoxetamine should be subjected to control measures across the Union.
Zbog zdravstvenih rizika koje on predstavlja, kao što je dokumentirano njegovim otkrivanjem u više prijavljenih smrtnih slučajeva, činjenice da ga korisnici mogu nesvjesno konzumirati i nepostojanja medicinske vrijednosti ili uporabe, metoksetamin bi trebalo podvrgnuti kontrolnim mjerama diljem Unije.
Given that nine Member States control methoxetamine under national legislation complying with the obligations of the 1971 United Nations Convention on Psychotropic Substances and nine Member States use other legislative measures to control it, subjecting this substance to control measures across the Union would help avoid the emergence of obstacles in cross-border law enforcement and judicial cooperation, and would protect against the risks that its availability and use can pose.
S obzirom na to da devet država članica kontrolira tvar metoksetamin u okviru nacionalnog zakonodavstva kojim se poštuju obveze na temelju Konvencije Ujedinjenih naroda o psihotropnim tvarima iz 1971. i da devet država članica upotrebljava druge zakonodavne mjere za njezinu kontrolu, podvrgavanje te tvari kontrolnim mjerama diljem Unije pomoglo bi izbjegavanju pojave prepreka u prekograničnom izvršavanju zakona i pravosudnoj suradnji te bi pružilo zaštitu od rizika koje dostupnost i uporaba te tvari mogu predstavljati.
Decision 2005/387/JHA confers upon the Council implementing powers with a view to giving a quick and expertise-based response at Union level to the emergence of new psychoactive substances detected and reported by the Member States, by subjecting those substances to control measures across the Union.
Odlukom 2005/387/PUP Vijeću se dodjeljuju provedbene ovlasti s ciljem davanja brzog i stručno utemeljenoga odgovora na razini Unije na pojavu novih psihoaktivnih tvari koje su otkrile i prijavile države članice, podvrgavanjem tih tvari kontrolnim mjerama diljem Unije.
As the conditions and procedure for triggering the exercise of such implementing powers have been met, an implementing decision should be adopted in order to put 25I-NBOMe, AH-7921, MDPV and methoxetamine under control across the Union.
Budući da su ispunjeni uvjeti i postupak za pokretanje izvršavanja takvih provedbenih ovlasti, trebalo bi donijeti provedbenu odluku kako bi se tvari 25I-NBOMe, AH-7921, MDPV i metoksetamin stavile pod kontrolu diljem Unije.
In its judgment of 16 April 2015 in Joined Cases C-317/13 and C-679/13 [3], the Court of Justice of the European Union held that prior to adopting an implementing decision on the basis of Article 8(3) of Decision 2005/387/JHA, the Council should consult the European Parliament.
U svojoj presudi od 16. travnja 2015. u spojenim predmetima C-317/13 i C-679/13 [3], Sud Europske unije smatrao je da bi se Vijeće, prije donošenja provedbenih odluka na temelju članka 8. stavka 3. Odluke 2005/387/PUP, trebalo savjetovati s Europskim parlamentom.
Council Implementing Decision 2014/688/EU [4] was adopted without such prior consultation and consequently is vitiated by a procedural defect.
Provedbena odluka Vijeća 2014/688/EU [4] donesena je bez takvog prethodnog savjetovanja te je stoga manjkava zbog povrede postupka.
Decision 2014/688/EU should, therefore, be replaced by this Decision.
Odluku 2014/688/EU trebalo bi stoga zamijeniti ovom Odlukom.
In order to ensure the continuity of control measures across the Union, as well as of the compliance with the obligations of the Member States under the 1971 United Nations Convention on Psychotropic Substances and under the 1961 United Nations Single Convention on Narcotic Drugs with regard to 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine), this Decision should be without prejudice to the obligations of the Member States relating to the time limit for subjecting those new psychoactive substances to control measures and criminal penalties in their national laws, as set out in Article 2 of Decision 2014/688/EU.
Kako bi se osigurali kontinuitet kontrolnih mjera širom Unije te sukladnost s obvezama država članica na temelju Konvencije Ujedinjenih naroda o psihotropnim tvarima iz 1971. i na temelju Jedinstvene konvencije Ujedinjenih naroda o opojnim drogama iz 1961. u odnosu na tvari 4-jodo-2,5-dimetoksi-N-(2-metoksibenzil)fenetilamina (25I-NBOMe), 3,4-dikloro-N-[[1-(dimetilamino)cikloheksil]metil]benzamida (AH-7921), 3,4-metilendioksipirovalerona (MDPV) i 2-(3-metoksifenil)-2-(etilamino)cikloheksanona (metoksetamin), ovom Odlukom ne bi se trebale dovoditi u pitanje obveze država članica u vezi s rokom za podvrgavanje tih novih psihoaktivnih tvari kontrolnim mjerama i kaznenim sankcijama u njihovim nacionalnim zakonodavstvima, kako je navedeno u članku 2. Odluke 2014/688/EU.
odo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe);
odo-2,5-dimetoksi-N-(2-metoksibenzil)fenetilamin (25I-NBOMe);
3,4-dichloro-N-[[1-dimethylamino)cyclohexyl]methyl]benzamide (AH-7921);
3,4-dikloro-N-[[1-(dimetilamino)cikloheksil]metil]benzamid (AH-7921);
Decision 2014/688/EU is replaced, without prejudice to the obligations of the Member States relating to the time limit for subjecting 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) to control measures and criminal penalties in their national laws, as set out in Article 2 of Decision 2014/688/EU.
Odluka 2014/688/EU zamjenjuje se ne dovodeći u pitanje obveze država članica u vezi s rokom za podvrgavanje tvari 4-jodo-2,5-dimetoksi-N-(2-metoksibenzil)fenetilamina (25I-NBOMe), 3,4-dikloro-N-[[1-(dimetilamino)cikloheksil]metil]benzamida (AH-7921), 3,4-metilendioksipirovalerona (MDPV) i 2-(3-metoksifenil)-2-(etilamino)cikloheksanona (metoksetamin) kontrolnim mjerama i kaznenim sankcijama u njihovim nacionalnim zakonodavstvima, kako je navedeno u članku 2. Odluke 2014/688/EU.
Council Decision 2003/847/JHA of 27 November 2003 concerning control measures and criminal sanctions in respect of the new synthetic drugs 2C-I, 2C-T-2, 2C-T-7 and TMA-2 (OJ L 321, 6.12.2003, p. 64).
Odluka Vijeća 2003/847/PUP od 27. studenoga 2003. o kontrolnim mjerama i kaznenim sankcijama vezanim za nove sintetičke droge 2C-I, 2C-T-2, 2C-T-7 i TMA-2 (SL L 321, 6.12.2003., str. 64.).
Judgment of the Court of Justice of 16 April 2015, Parliament v Council, Joined Cases C-317/13 and C-679/13, ECLI:EU:C:2015:223.
Presuda Suda od 16. travnja 2015., Parlament/Vijeće, spojeni predmeti C-317/13 i C-679/13, ECLI:EU:C:2015:223.
Council Implementing Decision 2014/688/EU of 25 September 2014 on subjecting 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine (25I-NBOMe), 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921), 3,4-methylenedioxypyrovalerone (MDPV) and 2-(3-methoxyphenyl)-2(ethylamino)cyclohexanone (methoxetamine) to control measures (OJ L 287, 1.10.2014, p. 22).
Provedbena odluka Vijeća 2014/688/EU od 25. rujna 2014. o podvrgavanju tvari 4-jodo-2,5-dimetoksi-N-(2-metoksibenzil)fenetilamina (25I-NBOMe), 3,4-dikloro-N-[[1-(dimetilamino)cikloheksil]metil]benzamida (AH-7921), 3,4-metilendioksipirovalerona (MDPV) i 2-(3-metoksifenil)-2-(etilamino)cikloheksanona (metoksetamin) kontrolnim mjerama (SL L 287, 1.10.2014., str. 22.).
Council Implementing Decision (EU) 2015/1876
Provedbena odluka Vijeća (EU) 2015/1876
on subjecting 5-(2-aminopropyl)indole to control measures
o podvrgavanju 5-(2-aminopropil)indola kontrolnim mjerama
A Risk Assessment Report on the new psychoactive substance 5-(2-aminopropyl)indole was drawn up in accordance with Article 6 of Decision 2005/387/JHA by the extended Scientific Committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) during a special session, and was subsequently submitted to the Commission and to the Council on 16 April 2013.
Izvješće o procjeni rizika za novu psihoaktivnu tvar 5-(2-aminopropil)indol sastavio je, u skladu s člankom 6. Odluke 2005/387/PUP, prošireni Znanstveni odbor Europskog centra za praćenje droga i ovisnosti o drogama (EMCDDA) na posebnoj sjednici te je naknadno dostavljeno Komisiji i Vijeću 16. travnja 2013.
5-(2-aminopropyl)indole has been found mostly in powder form but also in tablet and capsule form.
Tvar 5-(2-aminopropil)indol pojavljuje se većinom u obliku praha, ali i u obliku tableta i kapsula.
It is commercially available on the internet and from ‘head shops’, marketed as a ‘research chemical’.
Komercijalno je dostupna putem interneta i u specijaliziranim trgovinama (head shops), gdje se na tržište stavlja kao „istraživačka kemikalija”.
It has also been detected in samples of a product sold as a ‘legal high’ called ‘Benzo Fury’, and in tablets resembling ecstasy.
Također je otkrivena u uzorcima proizvoda koji se prodavao kao „legalna droga” pod nazivom „Benzo Fury” i u tabletama nalik ekstaziju.
The existing information and data suggest that the acute toxicity of 5-(2-aminopropyl)indole can provoke adverse effects in humans, such as tachycardia and hyperthermia, and may also cause mydriasis, agitation and tremor.
Postojeće informacije i podaci navode na zaključak da akutna toksičnost 5-(2-aminopropil)indola može izazvati štetne učinke kod ljudi, kao što su tahikardija i hipertermija, a može izazvati i midrijazu, uznemirenost i tremor.
5-(2-aminopropyl)indole may interact with other substances, including medical products and stimulants that act on the monoaminergic system.
Između 5-(2-aminopropil)indola i drugih tvari, uključujući lijekove i stimulanse koji djeluju na monoaminergički sustav, može doći do interakcije.
The specific physical effects of 5-(2-aminopropyl)indole in humans are difficult to determine because there are no published studies assessing its acute and chronic toxicity, its psychological and behavioural effects, or dependence potential, and because of the limited information and data available.
Posebne fizičke učinke 5-(2-aminopropil)indola kod ljudi teško je utvrditi zbog toga što ne postoje objavljene studije u kojima se procjenjuju njegova akutna i kronična toksičnost, njegove psihološke i bihevioralne posljedice ili ovisnički potencijal, kao i zbog ograničenosti dostupnih informacija i podataka.
There have been a total of 24 fatalities registered in four Member States from April to August 2012, in relation to which 5-(2-aminopropyl)indole alone, or in combination with other substances, was detected in post-mortem samples.
Između travnja i kolovoza 2012. zabilježena su ukupno 24 smrtna slučaja u četiri države članice, u vezi s kojima je 5-(2-aminopropil)indol, sam ili u kombinaciji s drugim tvarima, otkriven u obdukcijskim uzorcima.
While it is not possible to determine with certainty the role of 5-(2-aminopropyl)indole in all of the fatalities, in some cases it has been specifically noted in the cause of death.
Iako nije moguće sa sigurnošću utvrditi ulogu 5-(2-aminopropil)indola u svim tim smrtnim slučajevima, u nekim od njih on je posebno naveden kao jedan od uzroka smrti.
There is no information available on the social risks posed by 5-(2-aminopropyl)indole.
Nema dostupnih informacija o socijalnim rizicima koje predstavlja 5-(2-aminopropil)indol.
No prevalence data is available on the use of 5-(2-aminopropyl)indole, but the limited information that exists suggests that it may be consumed in similar environments as other stimulants, such as in the home, in bars and nightclubs or at music festivals.
Podaci o raširenosti uporabe 5-(2-aminopropil)indola nisu dostupni, ali ograničene informacije koje postoje ukazuju na to da ga se može konzumirati u sličnim uvjetima kao i ostale stimulanse, npr. kod kuće, u barovima i noćnim klubovima ili na glazbenim festivalima.
There is no information that suggests that 5-(2-aminopropyl)indole is manufactured in the Union, and there is no evidence suggesting the involvement of organised crime in the manufacture, distribution or supply of this new psychoactive substance.
Nema podataka koji ukazuju na to da se 5-(2-aminopropil)indol proizvodi u Uniji i nema dokaza koji ukazuju na uključenost organiziranog kriminala u proizvodnju i distribuciju ove nove psihoaktivne tvari ili opskrbu njome.
The substance 5-(2-aminopropyl)indole has no known, established or acknowledged medical value or use, and there is no marketing authorisation covering this new psychoactive substance in the Union.
Tvar 5-(2-aminopropil)indol nema poznatu, dokazanu ili priznatu medicinsku vrijednost ili uporabu niti postoji odobrenje za stavljanje ove nove psihoaktivne tvari na tržište u Uniji.
Apart from its use as an analytical reference standard and in scientific research, there is no indication that it is being used for other purposes.
Osim njezine uporabe kao analitičkog referentnog standarda i u znanstvenim istraživanjima, nema nikakvih naznaka da se nju upotrebljava za druge svrhe.
The substance 5-(2-aminopropyl)indole has not been, nor is it currently, under assessment by the United Nations' system, as defined in Decision 2005/387/JHA.
Tvar 5-(2-aminopropil)indol nije bila niti je trenutačno pod procjenom u okviru sustava Ujedinjenih naroda kako je definirano u Odluci 2005/387/PUP.
The Risk Assessment Report reveals that there is limited scientific evidence available on 5-(2-aminopropyl)indole and points out that further research would be needed to determine the health and social risks that it poses.
Iz izvješća o procjeni rizika proizlazi da su dostupni ograničeni znanstveni dokazi o 5-(2-aminopropil)indolu te se u njemu ističe da će biti potrebno daljnje istraživanje kako bi se utvrdili zdravstveni i socijalni rizici koje on predstavlja.
However, the available evidence and information provides sufficient ground for subjecting 5-(2-aminopropyl)indole to control measures across the Union.
Međutim, dostupni dokazi i informacije dovoljan su razlog za podvrgavanje 5-(2-aminopropil)indola kontrolnim mjerama širom Unije.
As a result of the health risks that it poses, as documented by its detection in several reported fatalities, of the fact that users may unknowingly consume it, and of the lack of medical value or use, 5-(2-aminopropyl)indole should be subjected to control measures across the Union.
Zbog zdravstvenih rizika koje on predstavlja, kao što je dokumentirano njegovim otkrivanjem u više prijavljenih smrtnih slučajeva, činjenice da ga korisnici mogu nesvjesno konzumirati i nepostojanja medicinske vrijednosti ili uporabe, 5-(2-aminopropil)indol trebalo bi podvrgnuti kontrolnim mjerama širom Unije.
Given that six Member States already control 5-(2-aminopropyl)indole by means of different types of legislative provisions, subjecting this substance to control measures across the Union would help avoid the emergence of obstacles in cross-border law enforcement and judicial cooperation, and protect users from the risks that its consumption can pose.
S obzirom na to da šest država članica već kontrolira 5-(2-aminopropil)indol putem različitih vrsta zakonodavnih odredaba, podvrgavanje te tvari kontrolnim mjerama širom Unije pomoglo bi izbjegavanju pojave prepreka u prekograničnom izvršavanju zakona i pravosudnoj suradnji te bi pružilo zaštitu korisnicima od rizika koje konzumacija te tvari može predstavljati.
As the conditions and procedure for triggering the exercise of such implementing powers have been met, an implementing decision should be adopted in order to put 5-(2-aminopropyl)indole under control across the Union.
Budući da su ispunjeni uvjeti i postupak za pokretanje izvršavanja takvih provedbenih ovlasti, trebalo bi donijeti provedbenu odluku kako bi se 5-(2-aminopropil)indol stavio pod kontrolu širom Unije.